Locally Advanced or Metastatic Unresectable Liposarcoma After Anthracycline-Based Therapy
This protocol addresses patients with locally advanced, metastatic, or clinically unresectable liposarcoma — a stage at which surgical cure is not possible and systemic treatment is given with palliative intent.
Anthracycline-based chemotherapy — doxorubicin-based regimens — is the established first-line standard for this presentation. Escalation to a subsequent line of treatment is indicated when this therapy fails to achieve or sustain partial response or stable disease, or when tumour progression occurs on or after treatment.
Second- and further-line treatment relies on histology-driven chemotherapy, with agents that have demonstrated specific activity in liposarcoma — including options evaluated in randomised controlled trials for this histology. The complete evidence-based regimen selection is detailed in the structured protocol.
References
DOI: 10.1016/j.annonc.2021.07.006
- Advanced/metastatic, clinically unresectable STS
- In patients with locally advanced/metastatic, non-resectable disease, systemic treatment with an essentially palliative intent can be proposed.
- Histology-driven ChT
- Trabectedin is an option in advanced STS in second and further lines of treatment. It has proved effective in LMS and liposarcoma [I, B; ESMO-MCBS v1.1 score: 2].
- A randomised phase III trial showed that eribulin was superior to dacarbazine in patients with liposarcomas and LMSs.
- Eribulin is an option in patients with liposarcomas [II, A; ESMO-MCBS v1.1 score: 3].